<i>In Vitro</i> Clonal Propagation of <i>Scoparia dulcis</i> L., a Perennial Medicinal Herb
An efficient protocol was established for in vitro clonal propagation of the perennial medicinal herb Scoparia dulcis L. (Family. Scrophulariaceae) through in vitro culture. Apical and axillary buds of young sprouts from selected plants were used as explants. Best shoot induction was observed on MS basal medium supplemented with 0.1 mg/l BAP, in which 94% of the explants produced 12 shoots per culture. Repeated subcultures in the same medium, resulted rapid shoot multiplication with 16 shoots per culture. The half strength MS medium with 0.5 mg/l IBA +0.5 mg/l NAA the highest percentage (85.20) and maximum number (13.40) of roots were initiated within four weeks of culture. For acclimatization and transplantation, the plantlets in the rooting culture tubes were kept in normal room temperature for 7 days before transplanting in pots where plantlets were reared for three weeks. The survival rate of regenerated plantlets was 85%.
Key words: Scoparia dulcis, Medicinal plant, Shoot proliferation, Micropropagation, Acclimatization, IAA (indoleacetic acid), IBA(indolebutanoic acid), NAA(α-naphthaleneacetic acid), BAP(benzylamino purine)
Bangladesh J. Sci. Ind. Res. 44(3), 341-346, 2009
Bangladesh Council of Scientific and Industrial Research (BCSIR) holds the copyright to all contents published in Bangladesh Journal of Scientific and Industrial Research (BJSIR). A copyright transfer form should be signed by the author(s) and be returned to BJSIR.
The entire contents of the BJSIR are protected under Bangladesh Council of Scientific and Industrial Research (BCSIR) copyrights.
BJSIR is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC) Creative Commons Attribution-NonCommercial 4.0 International License which allows others remix, tweak, and build upon the articles non-commercially, and although their new works must also acknowledge and be non-commercial, they dont have to license their derivative works on the same terms.